Pasireotide (SOM230), a Novel Multireceptor-Targeted Somatostatin Analogue, Is Well Tolerated When Administered as a Continuous 7-Day Subcutaneous Infusion in Healthy Male Volunteers-Reference-Cited by-同舟云学术

Pasireotide (SOM230), a Novel Multireceptor-Targeted Somatostatin Analogue, Is Well Tolerated When Administered as a Continuous 7-Day Subcutaneous Infusion in Healthy Male Volunteers

Published:2012-07 Issue:7 Volume:52 Page:1017-1027
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Petersenn Stephan,Unger Nicole,Hu Ke,Weisshaar Brigitte,Zhang Yilong,Bouillaud Emmanuel,Reséndiz Karina Hermosillo,Wang Yanfeng,Mann Klaus

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1177/0091270011408727/fullpdf

Reference14 articles.

1. Treatment of pituitary dependent Cushing's disease with the multi-receptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial;Boscaro;J Clin Endocrinol Metab,2009

2. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial;Petersenn;J Clin Endocrinol Metab,2010

3. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly;Ma;Clin Pharmacol Ther,2005

4. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients;Hoek;J Clin Endocrinol Metab,2004

5. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile;Bruns;Eur J Endocrinol,2002

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multidisciplinary management of difficult/aggressive growth-hormone pituitary neuro-endocrine tumors;Frontiers in Endocrinology;2023-05-03

2. Medical treatment of Cushing’s disease with concurrent diabetes mellitus;Frontiers in Endocrinology;2023-04-17

3. Second line treatment of acromegaly: Pasireotide or Pegvisomant?;Best Practice & Research Clinical Endocrinology & Metabolism;2022-12

4. Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials;Frontiers in Endocrinology;2020-12-08

5. Endocrinological Toxicity Secondary to Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs);Trends in Endocrinology & Metabolism;2020-03